Cargando…
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription. Here we sought to identify agents that synergize with BETi and to identify b...
Autores principales: | Yi, Joanna S., Sias-Garcia, Oscar, Nasholm, Nicole, Hu, Xiaoyu, Iniguez, Amanda Balboni, Hall, Matthew D., Davis, Mindy, Guha, Rajarshi, Moreno-Smith, Myrthala, Barbieri, Eveline, Duong, Kevin, Koach, Jessica, Qi, Jun, Bradner, James E., Stegmaier, Kimberly, Weiss, William A., Gustafson, W. Clay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192452/ https://www.ncbi.nlm.nih.gov/pubmed/34107377 http://dx.doi.org/10.1016/j.neo.2021.05.003 |
Ejemplares similares
-
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells
por: Čančer, Matko, et al.
Publicado: (2019) -
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2015) -
Design and Characterization of Bivalent BET Inhibitors
por: Tanaka, Minoru, et al.
Publicado: (2016) -
Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface
por: Massudi, Hassina, et al.
Publicado: (2023) -
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)